Benjamin Oakes' Scribe Therapeutics is developing specialized Crispr proteins for multiple diseases–and it’s got deals with Big Pharma potentially worth over $4 billion
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,